Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 30;gutjnl-2020-321411.
doi: 10.1136/gutjnl-2020-321411. Online ahead of print.

Outcomes of COVID-19 in 79 Patients With IBD in Italy: An IG-IBD Study

Affiliations
Free PMC article

Outcomes of COVID-19 in 79 Patients With IBD in Italy: An IG-IBD Study

Cristina Bezzio et al. Gut. .
Free PMC article

Abstract

Objectives: COVID-19 has rapidly become a major health emergency worldwide. Patients with IBD are at increased risk of infection, especially when they have active disease and are taking immunosuppressive therapy. The characteristics and outcomes of COVID-19 in patients with IBD remain unclear.

Design: This Italian prospective observational cohort study enrolled consecutive patients with an established IBD diagnosis and confirmed COVID-19. Data regarding age, sex, IBD (type, treatments and clinical activity), other comorbidities (Charlson Comorbidity Index (CCI)), signs and symptoms of COVID-19 and therapies were compared with COVID-19 outcomes (pneumonia, hospitalisation, respiratory therapy and death).

Results: Between 11 and 29 March 2020, 79 patients with IBD with COVID-19 were enrolled at 24 IBD referral units. Thirty-six patients had COVID-19-related pneumonia (46%), 22 (28%) were hospitalised, 7 (9%) required non-mechanical ventilation, 9 (11%) required continuous positive airway pressure therapy, 2 (3%) had endotracheal intubation and 6 (8%) died. Four patients (6%) were diagnosed with COVID-19 while they were being hospitalised for a severe flare of IBD. Age over 65 years (p=0.03), UC diagnosis (p=0.03), IBD activity (p=0.003) and a CCI score >1 (p=0.04) were significantly associated with COVID-19 pneumonia, whereas concomitant IBD treatments were not. Age over 65 years (p=0.002), active IBD (p=0.02) and higher CCI score were significantly associated with COVID-19-related death.

Conclusions: Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not. Preventing acute IBD flares may avoid fatal COVID-19 in patients with IBD. Further research is needed.

Keywords: IBD; epidemiology.

Conflict of interest statement

Competing interests: CB received lecture fees from Takeda, AbbVie and Janssen. SS received lecture fees from Takeda Pharmaceuticals and Janssen Pharmaceuticals and served as a consultant and a member of Advisory Boards for AbbVie and Janssen Pharmaceuticals. AV received lecture fees from Takeda and AbbVie and served as consultant for MSD, Pfizer and Janssen. MA received consulting fees from Nikkiso Europe and lecture fees from Janssen, Abbvie and Pfizer. CR reports personal fee from Abbvie, Janssen Cilag, MSD, Recordati, Takeda and Vifor. FC served as consultant and a member of advisory board for Mundipharma, AbbVie, MS&D, Takeda, Janssen, Roche, Celgene and received lecture fees from AbbVie, Amgen, Ferring, Takeda, Allergy Therapeutics and unrestricted research grants from Giuliani, Sofar, MSD, Takeda, AbbVie. FB served as a member of advisory board for Biogen and Janssen, Takeda, Celgene, Mundipharma, AbbVie and MSD. FC served as consultant and a member of advisory board for Mundipharma, AbbVie, MS&D, Takeda, Janssen, Roche, Celgene and received lecture fees from AbbVie, Amgen, Ferring, Takeda, Allergy Therapeutics. DGR served as consultant and received lecture fees from Janssen, Ferring, Errekappa. SD served as a speaker, consultant and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson and Johnson. MCF received fees as member of advisory boards and participation to sponsored symposia from AbbVie, Takeda, Jannsen-Cilag, Pfizer, Sandoz. AA served as a consultant for AbbVie, Allergan, Amgen, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz and Takeda; MD served as a speaker, consultant and advisory board member for AbbVie, Takeda, Janssen, Norgine, Pfizer, MSD, Celltrion, Roche, Gilead, Bioclinica, Ferring, SOFAR, Chiesi, Zambon. GF received consultancy fees from Ferring, MSD, AbbVie, Takeda, Janssen, Amgen, Sandoz, Samsung Bioepis, Celltrion.

Figures

Figure 1
Figure 1
Negative outcomes of COVID-19 in the overall IBD cohort, and for patients with Crohn’s disease (CD) and UC. CPAP, continuous positive airway pressure.

Similar articles

See all similar articles

References

    1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. 10.1038/s41586-020-2012-7 - DOI - PMC - PubMed
    1. World Health Organization Novel coronavirus (COVID-19) situation. Secondary novel coronavirus (COVID-19) situation, 2020. Available: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd
    1. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 2020;24:2012–9. 10.26355/eurrev_202002_20379 - DOI - PubMed
    1. Guan W-jie, Ni Z-yi, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020. doi:10.1001/jama.2020.4683. [Epub ahead of print: 23 Mar 2020]. - DOI - PubMed
Feedback